Zanubrutinib, lenalidomide and rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone as initial treatment in non–germinal center B-cell diffuse large B-cell lymphoma: a multi-center phase 2 study by Jiangsu Cooperative Lymphoma Group (JCLG)
Saved in:
| Title: | Zanubrutinib, lenalidomide and rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone as initial treatment in non–germinal center B-cell diffuse large B-cell lymphoma: a multi-center phase 2 study by Jiangsu Cooperative Lymphoma Group (JCLG) |
|---|---|
| Authors: | Xia, Yi1,2,3 (AUTHOR) cynthia0311@163.com, Miao, Yi1,2,3 (AUTHOR), Qian, Siqi1,2,3 (AUTHOR), Zhang, Run1,2,3 (AUTHOR), Qin, Shuchao1,2,3 (AUTHOR), Xie, Xiaoyan4 (AUTHOR), Li, Bingzong5 (AUTHOR), Sha, Yeqin1,2,3 (AUTHOR), Tang, Hanning1,2,3 (AUTHOR), Jin, Hui1,2,3 (AUTHOR), Cao, Lei1,2,3 (AUTHOR), Xu, Wei1,2,3 (AUTHOR), Fan, Lei1,2,3 (AUTHOR), Li, Jianyong1,2,3 (AUTHOR) lijianyonglm@163.com, Shi, Wenyu6,7 (AUTHOR) shiwenyu@hotmail.com, Zhu, Huayuan1,2,3 (AUTHOR) huayuan.zhu@hotmail.com |
| Source: | BMC Medicine. 10/24/2025, Vol. 23 Issue 1, p1-13. 13p. |
| Database: | Academic Search Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| FullText | Links: – Type: pdflink Text: Availability: 1 |
|---|---|
| Header | DbId: asn DbLabel: Academic Search Ultimate An: 188902936 AccessLevel: 2 PubType: Academic Journal PubTypeId: academicJournal PreciseRelevancyScore: 0 |
| IllustrationInfo | |
| Items | – Name: Title Label: Title Group: Ti Data: Zanubrutinib, lenalidomide and rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone as initial treatment in non–germinal center B-cell diffuse large B-cell lymphoma: a multi-center phase 2 study by Jiangsu Cooperative Lymphoma Group (JCLG) – Name: Author Label: Authors Group: Au Data: <searchLink fieldCode="AR" term="%22Xia%2C+Yi%22">Xia, Yi</searchLink><relatesTo>1,2,3</relatesTo> (AUTHOR)<i> cynthia0311@163.com</i><br /><searchLink fieldCode="AR" term="%22Miao%2C+Yi%22">Miao, Yi</searchLink><relatesTo>1,2,3</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Qian%2C+Siqi%22">Qian, Siqi</searchLink><relatesTo>1,2,3</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Zhang%2C+Run%22">Zhang, Run</searchLink><relatesTo>1,2,3</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Qin%2C+Shuchao%22">Qin, Shuchao</searchLink><relatesTo>1,2,3</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Xie%2C+Xiaoyan%22">Xie, Xiaoyan</searchLink><relatesTo>4</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Li%2C+Bingzong%22">Li, Bingzong</searchLink><relatesTo>5</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Sha%2C+Yeqin%22">Sha, Yeqin</searchLink><relatesTo>1,2,3</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Tang%2C+Hanning%22">Tang, Hanning</searchLink><relatesTo>1,2,3</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Jin%2C+Hui%22">Jin, Hui</searchLink><relatesTo>1,2,3</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Cao%2C+Lei%22">Cao, Lei</searchLink><relatesTo>1,2,3</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Xu%2C+Wei%22">Xu, Wei</searchLink><relatesTo>1,2,3</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Fan%2C+Lei%22">Fan, Lei</searchLink><relatesTo>1,2,3</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Li%2C+Jianyong%22">Li, Jianyong</searchLink><relatesTo>1,2,3</relatesTo> (AUTHOR)<i> lijianyonglm@163.com</i><br /><searchLink fieldCode="AR" term="%22Shi%2C+Wenyu%22">Shi, Wenyu</searchLink><relatesTo>6,7</relatesTo> (AUTHOR)<i> shiwenyu@hotmail.com</i><br /><searchLink fieldCode="AR" term="%22Zhu%2C+Huayuan%22">Zhu, Huayuan</searchLink><relatesTo>1,2,3</relatesTo> (AUTHOR)<i> huayuan.zhu@hotmail.com</i> – Name: TitleSource Label: Source Group: Src Data: <searchLink fieldCode="JN" term="%22BMC+Medicine%22">BMC Medicine</searchLink>. 10/24/2025, Vol. 23 Issue 1, p1-13. 13p. |
| PLink | https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=asn&AN=188902936 |
| RecordInfo | BibRecord: BibEntity: Identifiers: – Type: doi Value: 10.1186/s12916-025-04418-y Languages: – Code: eng Text: English PhysicalDescription: Pagination: PageCount: 13 StartPage: 1 Titles: – TitleFull: Zanubrutinib, lenalidomide and rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone as initial treatment in non–germinal center B-cell diffuse large B-cell lymphoma: a multi-center phase 2 study by Jiangsu Cooperative Lymphoma Group (JCLG) Type: main BibRelationships: HasContributorRelationships: – PersonEntity: Name: NameFull: Xia, Yi – PersonEntity: Name: NameFull: Miao, Yi – PersonEntity: Name: NameFull: Qian, Siqi – PersonEntity: Name: NameFull: Zhang, Run – PersonEntity: Name: NameFull: Qin, Shuchao – PersonEntity: Name: NameFull: Xie, Xiaoyan – PersonEntity: Name: NameFull: Li, Bingzong – PersonEntity: Name: NameFull: Sha, Yeqin – PersonEntity: Name: NameFull: Tang, Hanning – PersonEntity: Name: NameFull: Jin, Hui – PersonEntity: Name: NameFull: Cao, Lei – PersonEntity: Name: NameFull: Xu, Wei – PersonEntity: Name: NameFull: Fan, Lei – PersonEntity: Name: NameFull: Li, Jianyong – PersonEntity: Name: NameFull: Shi, Wenyu – PersonEntity: Name: NameFull: Zhu, Huayuan IsPartOfRelationships: – BibEntity: Dates: – D: 24 M: 10 Text: 10/24/2025 Type: published Y: 2025 Identifiers: – Type: issn-print Value: 17417015 Numbering: – Type: volume Value: 23 – Type: issue Value: 1 Titles: – TitleFull: BMC Medicine Type: main |
| ResultId | 1 |
